MeiraGTx (MGTX) Q3 2026 earnings summary

Executive summary

• 9M net income was $63.1M, primarily from non-recurring collaboration and license transactions; Q3 net loss was $51.3M, with no product sales generated.

• Cash, cash equivalents and restricted cash totaled $186.8M at Sept. 30, 2026; expected Hologen funding and reimbursements are projected to support operations into H2 2028.

Financial highlights

• Q3 revenue was $4.8M vs. $0.4M YoY; operating expenses were $54.7M vs. $46.5M, and operating loss was $49.9M vs. $46.1M.

• 9M revenue was $326.5M vs. $6.0M, including $204.6M related-party license revenue and $108.4M related-party service revenue; operating income was $153.7M vs. a $132.4M loss.

• 9M net income was $63.1M vs. a $129.3M net loss, reflecting non-recurring transactions including Hologen collaboration revenue.

• Q3 net loss was $51.3M, or $0.53 per basic and diluted share, vs. $50.5M and $0.62 per share YoY; R&D rose to $39.3M from $32.5M while G&A fell to $12.0M from $13.6M.

Outlook and guidance

• Bota-vec MAA dossier is complete, with EMA submission intended for Dec. 2026 subject to confirmation; full FDA BLA submission is expected in Q1 2027, with preparations for a potential late-2027 launch.

• AQUAx2 completed enrollment in Q2 2026; pivotal 12-month data are expected mid-2027 and could support a BLA by year-end 2027 and U.S. approval in 2028 if positive.

• Reogen plans to initiate a Phase 3 AAV-GAD study in Q1 2027; a SAD/MAD study of the riboswitch platform’s lead small molecule is expected to begin in Dec. 2026.

• IND-enabling priorities include Ribo-Leptin and a riboswitch neuropathic-pain program; first-in-human combination studies are planned for 2027.

• Significant operating losses and R&D and G&A costs are expected to continue; additional capital may be needed and may not be available on acceptable terms.